Connect Biopharma (CNTB) Reports Positive Phase 2 Asthma and COPD Data
Connect Biopharma reported positive preliminary Phase 2 data for rademikibart in treating asthma and COPD. The company plans to discuss potential Phase 3 programs with the FDA in late 2026 for asthma and early 2027 for COPD.
How this was made

The 30-second read
Why it matters
The data represents the first public disclosure of the Phase 2 results, making it a primary source of new information.
Market read
First‑report positive Phase 2 data provides a fresh catalyst that could move the stock in the short term.
What to watch
Potential regulatory delays or competitive trial outcomes could temper the upside.
Background
Connect Biopharma is a clinical‑stage company focused on respiratory diseases; the press release was distributed via GlobeNewswire.
Ticker impact
Connect Biopharma reported positive Phase 2 topline data for its asthma and COPD drug candidate.
likely upward pressure as market prices in the favorable trial results
Phase 2 success is a material catalyst for a biotech; no comparable data was previously public.
Market effects
Positive asthma/COPD data could boost sentiment toward respiratory‑therapy biotech peers.
May lift Asian‑listed biotech indices where Connect Biopharma is also listed.
Adds to the pipeline optimism trend in the global biotech sector.
Counterpoint
Investors may wait for Phase 3 data before committing, as early‑stage results can be non‑binding.
Key entities
- companyConnect Biopharma Holdings Limited
Biopharma company developing rademikibart for asthma and COPD.
